Department of Biomedical Engineering, Seoul National University College of Medicine, Seoul, Republic of Korea (South).
Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea (South).
Clin Cancer Res. 2021 Jun 15;27(12):3370-3382. doi: 10.1158/1078-0432.CCR-20-3513. Epub 2021 Feb 16.
Pancreatic ductal adenocarcinoma (PDAC) subtypes have been identified using various methodologies. However, it is a challenge to develop classification system applicable to routine clinical evaluation. We aimed to identify risk subgroups based on molecular features and develop a classification model that was more suited for clinical applications.
We collected whole dissected specimens from 225 patients who underwent surgery at Seoul National University Hospital [Seoul, Republic of Korea (South)], between October 2009 and February 2018. Target proteins with potential relevance to tumor progression or prognosis were quantified with robust quality controls. We used hierarchical clustering analysis to identify risk subgroups. A random forest classification model was developed to predict the identified risk subgroups, and the model was validated using transcriptomic datasets from external cohorts ( = 700), with survival analysis.
We identified 24 protein features that could classify the four risk subgroups associated with patient outcomes: stable, exocrine-like; activated, and extracellular matrix (ECM) remodeling. The "stable" risk subgroup was characterized by proteins that were associated with differentiation and tumor suppressors. "Exocrine-like" tumors highly expressed pancreatic enzymes. Two high-risk subgroups, "activated" and "ECM remodeling," were enriched in terms such as cell cycle, angiogenesis, immunocompetence, tumor invasion metastasis, and metabolic reprogramming. The classification model that included these features made prognoses with relative accuracy and precision in multiple cohorts.
We proposed PDAC risk subgroups and developed a classification model that may potentially be useful for routine clinical implementations, at the individual level. This clinical system may improve the accuracy of risk prediction and treatment guidelines..
已经使用各种方法鉴定了胰腺导管腺癌(PDAC)亚型。然而,开发适用于常规临床评估的分类系统是一个挑战。我们旨在根据分子特征确定风险亚组,并开发更适合临床应用的分类模型。
我们收集了 2009 年 10 月至 2018 年 2 月在首尔国立大学医院(韩国首尔)接受手术的 225 名患者的全解剖标本。使用稳健的质量控制来定量具有潜在与肿瘤进展或预后相关的靶蛋白。我们使用层次聚类分析来识别风险亚组。开发了随机森林分类模型来预测鉴定的风险亚组,并使用外部队列的转录组数据集(n = 700)进行验证,同时进行生存分析。
我们确定了 24 种蛋白质特征,这些特征可以将与患者结局相关的四个风险亚组分类:稳定、外分泌样;激活和细胞外基质(ECM)重塑。“稳定”风险亚组的特征是与分化和肿瘤抑制相关的蛋白质。“外分泌样”肿瘤高度表达胰腺酶。两个高风险亚组,“激活”和“ECM 重塑”,在细胞周期、血管生成、免疫能力、肿瘤侵袭转移和代谢重编程等方面得到了丰富。包含这些特征的分类模型在多个队列中具有相对准确和精确的预后。
我们提出了 PDAC 风险亚组,并开发了一种分类模型,该模型可能在个体水平上对常规临床实施具有潜在的用处。该临床系统可能会提高风险预测和治疗指南的准确性。